DE10137633A1 - Pramipexol zur Behandlung von ADHD - Google Patents
Pramipexol zur Behandlung von ADHDInfo
- Publication number
- DE10137633A1 DE10137633A1 DE10137633A DE10137633A DE10137633A1 DE 10137633 A1 DE10137633 A1 DE 10137633A1 DE 10137633 A DE10137633 A DE 10137633A DE 10137633 A DE10137633 A DE 10137633A DE 10137633 A1 DE10137633 A1 DE 10137633A1
- Authority
- DE
- Germany
- Prior art keywords
- acid
- use according
- pramipexole
- treatment
- prevention
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000003839 salts Chemical class 0.000 title claims abstract description 17
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 title claims abstract description 13
- 238000011282 treatment Methods 0.000 title claims abstract description 11
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 title claims description 11
- 238000011321 prophylaxis Methods 0.000 title abstract 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 title description 3
- 239000003136 dopamine receptor stimulating agent Substances 0.000 title description 2
- FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 claims abstract description 25
- 239000002253 acid Substances 0.000 claims abstract description 10
- FASDKYOPVNHBLU-UHFFFAOYSA-N N6-Propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine Chemical compound C1C(NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-UHFFFAOYSA-N 0.000 claims abstract description 9
- 239000003814 drug Substances 0.000 claims abstract description 8
- 239000012453 solvate Substances 0.000 claims abstract description 8
- 229960003089 pramipexole Drugs 0.000 claims description 23
- 208000013403 hyperactivity Diseases 0.000 claims description 11
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical class CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical class Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 150000004677 hydrates Chemical class 0.000 claims description 8
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical class OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical class OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 6
- 230000006735 deficit Effects 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 5
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical class OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Chemical class OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 4
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 claims description 3
- YFGHCGITMMYXAQ-UHFFFAOYSA-N 2-[(diphenylmethyl)sulfinyl]acetamide Chemical compound C=1C=CC=CC=1C(S(=O)CC(=O)N)C1=CC=CC=C1 YFGHCGITMMYXAQ-UHFFFAOYSA-N 0.000 claims description 3
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical class NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 claims description 3
- DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 3
- 229940025084 amphetamine Drugs 0.000 claims description 3
- 239000000935 antidepressant agent Substances 0.000 claims description 3
- 229940005513 antidepressants Drugs 0.000 claims description 3
- 229960002430 atomoxetine Drugs 0.000 claims description 3
- VHGCDTVCOLNTBX-QGZVFWFLSA-N atomoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=CC=C1C VHGCDTVCOLNTBX-QGZVFWFLSA-N 0.000 claims description 3
- 229960001344 methylphenidate Drugs 0.000 claims description 3
- 229960001165 modafinil Drugs 0.000 claims description 3
- NRNCYVBFPDDJNE-UHFFFAOYSA-N pemoline Chemical compound O1C(N)=NC(=O)C1C1=CC=CC=C1 NRNCYVBFPDDJNE-UHFFFAOYSA-N 0.000 claims description 3
- 229960000761 pemoline Drugs 0.000 claims description 3
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 claims description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Chemical class OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 2
- NFHVTCJKAHYEQN-UHFFFAOYSA-N amfetaminil Chemical compound C=1C=CC=CC=1C(C#N)NC(C)CC1=CC=CC=C1 NFHVTCJKAHYEQN-UHFFFAOYSA-N 0.000 claims description 2
- 229950000762 amfetaminil Drugs 0.000 claims description 2
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 claims description 2
- 229960001058 bupropion Drugs 0.000 claims description 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical class O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims description 2
- 229960003914 desipramine Drugs 0.000 claims description 2
- 239000001530 fumaric acid Chemical class 0.000 claims description 2
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 claims description 2
- 229960004801 imipramine Drugs 0.000 claims description 2
- 239000004310 lactic acid Substances 0.000 claims description 2
- 235000014655 lactic acid Nutrition 0.000 claims description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 2
- 239000011976 maleic acid Substances 0.000 claims description 2
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 claims description 2
- 229940098779 methanesulfonic acid Drugs 0.000 claims description 2
- 239000011975 tartaric acid Substances 0.000 claims description 2
- 235000002906 tartaric acid Nutrition 0.000 claims description 2
- 230000003449 preventive effect Effects 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 2
- 230000000694 effects Effects 0.000 description 7
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 229950010601 pramipexole dihydrochloride monohydrate Drugs 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 235000011054 acetic acid Nutrition 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000003946 Prolactin Human genes 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 241001620634 Roger Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229960002652 pramipexole dihydrochloride Drugs 0.000 description 1
- 229940097325 prolactin Drugs 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 1
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- VQMNWIMYFHHFMC-UHFFFAOYSA-N tert-butyl 4-hydroxyindole-1-carboxylate Chemical compound C1=CC=C2N(C(=O)OC(C)(C)C)C=CC2=C1O VQMNWIMYFHHFMC-UHFFFAOYSA-N 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10137633A DE10137633A1 (de) | 2001-08-03 | 2001-08-03 | Pramipexol zur Behandlung von ADHD |
| US10/198,480 US20030036555A1 (en) | 2001-08-03 | 2002-07-18 | Pramipexole for the treatment of ADHD |
| CA002453485A CA2453485A1 (en) | 2001-08-03 | 2002-07-31 | Pramipexole for the treatment of adhd |
| EP02762417A EP1416930A1 (de) | 2001-08-03 | 2002-07-31 | Pramipexol zur behandlung von adhd |
| PCT/EP2002/008500 WO2003013520A1 (de) | 2001-08-03 | 2002-07-31 | Pramipexol zur behandlung von adhd |
| MXPA04001001A MXPA04001001A (es) | 2001-08-03 | 2002-07-31 | PRAMIPEXOL PARA EL TRATAMIENTO DEL TRASTORNO DE HIPERACTIVIDAD Y DeFICIT DE LA ATENCION. |
| JP2003518529A JP2005500368A (ja) | 2001-08-03 | 2002-07-31 | Ａｄｈｄ治療用プラミペクソール |
| UY27408A UY27408A1 (es) | 2001-08-03 | 2002-08-02 | Pramipexol para el tratamiento del adhd. |
| ARP020102946A AR035273A1 (es) | 2001-08-03 | 2002-08-02 | Pramipexol para el tratamiento del adhd |
| US10/958,156 US20050049289A1 (en) | 2001-08-03 | 2004-10-04 | Pramipexole for the treatment ADHD |
| US12/039,243 US20080146628A1 (en) | 2001-08-03 | 2008-02-28 | Pramipexole for the treatment of adhd |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10137633A DE10137633A1 (de) | 2001-08-03 | 2001-08-03 | Pramipexol zur Behandlung von ADHD |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE10137633A1 true DE10137633A1 (de) | 2003-02-20 |
Family
ID=7693957
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE10137633A Withdrawn DE10137633A1 (de) | 2001-08-03 | 2001-08-03 | Pramipexol zur Behandlung von ADHD |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP1416930A1 (https=) |
| JP (1) | JP2005500368A (https=) |
| AR (1) | AR035273A1 (https=) |
| CA (1) | CA2453485A1 (https=) |
| DE (1) | DE10137633A1 (https=) |
| MX (1) | MXPA04001001A (https=) |
| UY (1) | UY27408A1 (https=) |
| WO (1) | WO2003013520A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TR200906997A1 (tr) | 2009-09-11 | 2011-03-21 | Sanovel �La� San. Ve T�C. A. �. | Pramipeksol farmasötik bileşimleri. |
| TR200907554A1 (tr) * | 2009-10-06 | 2011-04-21 | Sanovel İlaç San.Ve Ti̇c.A.Ş. | Oral yolla dağılan pramıpexole bileşimleri. |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5621133A (en) * | 1989-05-31 | 1997-04-15 | Deninno; Michael P. | Dopamine agonists |
| US7049337B2 (en) * | 2000-05-19 | 2006-05-23 | Wayne State University | Derivatives of 2-aminotetralins and pharmaceutical analogs thereof exhibiting differential CNS receptor activity and behavior |
| US20020016334A1 (en) * | 2000-07-31 | 2002-02-07 | Coe Jotham Wadsworth | Pharmaceutical composition for the treatment of attention deficit hyperactivity disorder (ADHD) |
| US6613308B2 (en) * | 2000-09-19 | 2003-09-02 | Advanced Inhalation Research, Inc. | Pulmonary delivery in treating disorders of the central nervous system |
-
2001
- 2001-08-03 DE DE10137633A patent/DE10137633A1/de not_active Withdrawn
-
2002
- 2002-07-31 JP JP2003518529A patent/JP2005500368A/ja active Pending
- 2002-07-31 WO PCT/EP2002/008500 patent/WO2003013520A1/de not_active Ceased
- 2002-07-31 CA CA002453485A patent/CA2453485A1/en not_active Abandoned
- 2002-07-31 EP EP02762417A patent/EP1416930A1/de not_active Withdrawn
- 2002-07-31 MX MXPA04001001A patent/MXPA04001001A/es not_active Application Discontinuation
- 2002-08-02 UY UY27408A patent/UY27408A1/es not_active Application Discontinuation
- 2002-08-02 AR ARP020102946A patent/AR035273A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AR035273A1 (es) | 2004-05-05 |
| EP1416930A1 (de) | 2004-05-12 |
| CA2453485A1 (en) | 2003-02-20 |
| JP2005500368A (ja) | 2005-01-06 |
| MXPA04001001A (es) | 2004-04-20 |
| WO2003013520A1 (de) | 2003-02-20 |
| UY27408A1 (es) | 2003-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69623141T2 (de) | Verwendung von Tomoxetin zur Behandlung von Hyperaktivität mit Aufmerksamkeitsstörungen | |
| DE69400799T2 (de) | Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen | |
| JP6527290B2 (ja) | 製薬領域における右旋性オキシラセタムの応用 | |
| HUE026484T2 (en) | Alpha-aminoamide derivatives useful in the treatment of cognitive disorders | |
| JP7436524B2 (ja) | ハンチントン病及びその症状を治療するためのプリドピジン及びその類似体を含む組成物 | |
| JPH0318602B2 (https=) | ||
| EP1289528A1 (de) | Wirkstoffkombination enthaltend ein opioid mit fentanyl-artiger struktur und ketamin | |
| DE60220043T2 (de) | Carbamatverbindungen zur vorbeugung oder behandlung von neurodegenerativen störungen | |
| DE60122015T2 (de) | Behandlung affektiver störungen durch kombinierte wirkung eines nikotinischen rezeptoragonisten und einer monoaminergischen substanz | |
| DE69231955T2 (de) | Verwendung von N-(2,6-Dimethylphenyl)-2-(2-oxo-1-pyrrolidinyl)acetamid zur Behandlung von Demenz | |
| DE10148233A1 (de) | Verbindungen zur Reduzierung übermäßiger Nahrungsaufnahme | |
| DE3213788A1 (de) | Analgetikum und dessen anwendung | |
| DE60216457T2 (de) | Carbamate verbindungen zur behandlung oder verhutung von psychotischen krankheiten | |
| DE69923081T2 (de) | Desmethylolanzapine enthaltende zusammensetzungen und verfahren | |
| DE69529819T2 (de) | Neue kombination eines betablockers mit einem lokalanästhetikum | |
| DE10137633A1 (de) | Pramipexol zur Behandlung von ADHD | |
| US20080146628A1 (en) | Pramipexole for the treatment of adhd | |
| DE69328307T2 (de) | Kombination von atovaquone mit proguanil zur behandlung von protozoeninfektion | |
| DE69907220T2 (de) | Verwendung von substanz p antagonisten zur behandlung des chronischen ermüdungssyndroms und/oder der fibromyalgie | |
| CN104623671B (zh) | 含有乙酰胆碱酯酶抑制剂和二甲双胍的复方药用组合物 | |
| EP1418908A1 (de) | Verbindungen zur beseitigung und/oder linderung der anhedonie | |
| DE60112750T2 (de) | Pharmazeutische zusammensetzung enthaltend famotidine für die behandlung von depressionen | |
| DE10312809A1 (de) | Pramipexol zur Reduzierung übermäßiger Nahrungsaufnahme bei Kindern | |
| EP1414446B1 (de) | Pramipexol als antikonvulsivum | |
| Westenberg | Atypical neuroleptics in acute schizophrenia: a double-blind comparative study of remoxipride and haloperidol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8127 | New person/name/address of the applicant |
Owner name: BOEHRINGER INGELHEIM PHARMA GMBH & CO.KG, 55218 IN |
|
| 8141 | Disposal/no request for examination |